Rainbow Extension Study (RainbowExt)

Condition

Retinopathy of Prematurity

Interventions

Drug:Ranibizumab

ClinicalTrials.gov identifier

NCT02640664

Novartis reference number

CRFB002H2301E1

Phase

Phase 3

This study is Active, not recruiting.

Official title

RAINBOW Extension Study: an Extension Study to Evaluate the Long Term Efficacy and Safety of RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity

Purpose

The purpose of this study is to evaluate the long term efficacy and safety of intravitreal ranibizumab compared with laser ablation therapy in patients who were treated for retinopathy of prematurity (ROP) in the core study CRFB002H2301

This website intends to use cookies to improve the site and your experience. By continuing to browse the site you are agreeing to accept our use of cookies. If you require further information and/or do not wish to have cookies placed when using the site, visit About cookies page.